JP2006508987A - ホスホジエステラーゼ４阻害剤 - Google Patents

ホスホジエステラーゼ４阻害剤 Download PDF

Info

Publication number
JP2006508987A
JP2006508987A JP2004553941A JP2004553941A JP2006508987A JP 2006508987 A JP2006508987 A JP 2006508987A JP 2004553941 A JP2004553941 A JP 2004553941A JP 2004553941 A JP2004553941 A JP 2004553941A JP 2006508987 A JP2006508987 A JP 2006508987A
Authority
JP
Japan
Prior art keywords
alkyl
substituted
pyridylmethyl
oxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2004553941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006508987A5 (cg-RX-API-DMAC7.html
Inventor
リチャード エー． シュマシェール
ドーリー グラハム，エリザベス
ティー． ホッパー，アレン
テヒム，アショク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memory Pharmaceuticals Corp
Original Assignee
Memory Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharmaceuticals Corp filed Critical Memory Pharmaceuticals Corp
Publication of JP2006508987A publication Critical patent/JP2006508987A/ja
Publication of JP2006508987A5 publication Critical patent/JP2006508987A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2004553941A 2002-11-19 2003-11-19 ホスホジエステラーゼ４阻害剤 Ceased JP2006508987A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42722102P 2002-11-19 2002-11-19
PCT/US2003/036986 WO2004046113A2 (en) 2002-11-19 2003-11-19 Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors

Publications (2)

Publication Number Publication Date
JP2006508987A true JP2006508987A (ja) 2006-03-16
JP2006508987A5 JP2006508987A5 (cg-RX-API-DMAC7.html) 2007-02-15

Family

ID=32326501

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004553941A Ceased JP2006508987A (ja) 2002-11-19 2003-11-19 ホスホジエステラーゼ４阻害剤

Country Status (16)

Country Link
US (3) US7087625B2 (cg-RX-API-DMAC7.html)
EP (1) EP1569908B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006508987A (cg-RX-API-DMAC7.html)
KR (1) KR20050075430A (cg-RX-API-DMAC7.html)
CN (1) CN100513397C (cg-RX-API-DMAC7.html)
AT (1) ATE481387T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003295656B2 (cg-RX-API-DMAC7.html)
BR (1) BR0315705A (cg-RX-API-DMAC7.html)
CA (1) CA2506297A1 (cg-RX-API-DMAC7.html)
DE (1) DE60334243D1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05005345A (cg-RX-API-DMAC7.html)
NO (1) NO20052976L (cg-RX-API-DMAC7.html)
NZ (1) NZ540138A (cg-RX-API-DMAC7.html)
RU (1) RU2356893C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004046113A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200503995B (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513957A (ja) * 2003-12-11 2007-05-31 メモリー ファーマシューティカルス コーポレーション Ｎ−置換ジアリールアミン類縁体を含む，ホスホジエステラーゼ４阻害剤本出願は，参照によりその全開示がここに導入されている２００３年１２月１１日に提出した米国仮出願番号６０／５２８，４８６の利益を請求するものである。
WO2008105386A1 (ja) * 2007-02-27 2008-09-04 National University Corporation Okayama University アルコキシ基を有するレキシノイド化合物
WO2010041449A1 (ja) * 2008-10-09 2010-04-15 国立大学法人 岡山大学 Rxr作動性物質を有効成分とする抗アレルギー剤
JP2011517687A (ja) * 2008-04-14 2011-06-16 シエシー ファルマセウティチィ ソシエタ ペル アチオニ ホスホジエステラーゼ−４阻害剤としての第３アミン誘導体

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US20030149052A1 (en) * 2002-01-22 2003-08-07 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
AU2003256616B2 (en) * 2002-07-19 2009-08-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
DE60325984D1 (de) * 2002-07-19 2009-03-12 Memory Pharmaceutical Corp 4-aminobenzofuranverbindungen als phosphodiesterase-4-inhibitoren
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
AU2003282726B2 (en) * 2002-10-03 2010-10-07 Targegen, Inc. Vasculostatic agents and methods of use thereof
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
ES2251866B1 (es) * 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) * 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
US7652051B2 (en) 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
JP2008543781A (ja) * 2005-06-10 2008-12-04 メモリー・ファーマシューティカルズ・コーポレイション ホスフオジエステラーゼ４阻害剤
ES2320954B1 (es) * 2007-03-02 2010-03-16 Laboratorio Almirall S.A. Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona.
KR20100014565A (ko) * 2007-04-11 2010-02-10 알콘 리서치, 리미티드 알레르기성 비염 및 알레르기성 결막염을 치료하기 위한 ｔｎｆａ의 억제제 및 항히스타민의 용도
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
WO2009067607A2 (en) * 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
EP2070913A1 (en) 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
CN102548536A (zh) * 2009-10-01 2012-07-04 爱尔康研究有限公司 奥洛他定组合物及其用途
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
JP6282721B2 (ja) 2013-03-14 2018-02-21 ダート・ニューロサイエンス・（ケイマン）・リミテッド Ｐｄｅ４阻害剤としての置換ピリジン及びピラジン化合物

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004046A1 (en) * 1993-07-28 1995-02-09 Rhone-Poulenc Rorer Limited Compounds as pde iv and tnf inhibitors
JPH09509654A (ja) * 1994-01-26 1997-09-30 ローン−プーラン・ロレ・リミテツド サイクリックａｍｐホスホジエステラーゼおよびｔｎｆ阻害剤としての置換芳香族化合物
JPH11189577A (ja) * 1997-12-25 1999-07-13 Nikken Chem Co Ltd ３−アニリノ−２−シクロアルケノン誘導体
JP2000501742A (ja) * 1995-12-15 2000-02-15 メルク フロスト カナダ アンド カンパニー Ｐｄｅ▲ｉｖ▼阻害剤としてのトリアリールエタン誘導体
JP2000509719A (ja) * 1996-06-19 2000-08-02 ローン―プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
WO2001070738A2 (en) * 2000-03-23 2001-09-27 Merck Frosst Canada & Co. Tri-aryl-substituted-ethane pde4 inhibitors
WO2001090076A1 (en) * 2000-05-25 2001-11-29 Merck Frosst Canada & Co. Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
JP2002502851A (ja) * 1998-02-09 2002-01-29 ダーウィン・ディスカバリー・リミテッド ベンゾフラン−４−カルボキサミドとその治療的使用
WO2002074726A2 (en) * 2001-01-22 2002-09-26 Memory Pharmaceuticals Corporation Aniline derivatives useful as phosphodiesterase 4 inhibitors
JP2002537383A (ja) * 1999-02-25 2002-11-05 メルク フロスト カナダ アンド カンパニー Ｐｄｅｉｖ阻害化合物、組成物および治療方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311281D0 (en) 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
US5698711A (en) 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US5935978A (en) 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US6096768A (en) 1992-01-28 2000-08-01 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
ES2102036T3 (es) 1992-06-15 1997-07-16 Celltech Therapeutics Ltd Derivados con grupo fenilo trisustituido utilizados como inhibidores selectivos de la fosfodiesterasa iv.
US5679696A (en) 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
CZ14795A3 (en) 1992-07-28 1996-07-17 Rhone Poulenc Rorer Ltd Benzene derivative containing phenyl group bound to aryl or heteroaryl fraction through an aliphatic or hetero atom containing group, process of its preparation and pharmaceutical composition containing thereof
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
TW263495B (cg-RX-API-DMAC7.html) 1992-12-23 1995-11-21 Celltech Ltd
US5622977A (en) 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
RU2083562C1 (ru) * 1993-02-05 1997-07-10 Исихара Сангио Кайся Лтд. Производные пиридина, способ их получения, инсектицидная композиция
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
AU6971894A (en) 1993-05-27 1994-12-20 Smithkline Beecham Laboratoires Pharmaceutiques Anti-arrhythmic n-substituted 3-benzazepines or isoquinolines
DE59410119D1 (de) 1993-07-02 2002-06-20 Byk Gulden Lomberg Chem Fab Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
EP0738268B1 (en) 1993-12-22 2004-03-03 Celltech R&D Limited Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors
GB9326600D0 (en) 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
FR2729142A1 (fr) 1995-01-06 1996-07-12 Smithkline Beecham Lab Nouvelles amines heterocycliques, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu'agents anti-arythmiques
US5731477A (en) 1995-01-31 1998-03-24 Smithkline Beecham Corporation Method for synthesis of aryl difluoromethyl ethers
IT1275433B (it) 1995-05-19 1997-08-07 Smithkline Beecham Farma Derivati di diarildiammine
AU5772196A (en) 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
FR2735777B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
GB9603723D0 (en) 1996-02-22 1996-04-24 Merck & Co Inc Diphenyl pyridyl derivatives as pde iv inhibitors
US5710170A (en) 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
GB9526243D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
SI0912558T1 (en) 1996-06-25 2003-10-31 Pfizer Inc. Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
JPH1072415A (ja) 1996-06-26 1998-03-17 Nikken Chem Co Ltd ３−アニリノ−２−シクロアルケノン誘導体
EA002113B1 (ru) 1996-09-04 2001-12-24 Пфайзер Инк. Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно)
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
GB9625184D0 (en) 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
CA2295106C (en) * 1997-06-24 2007-03-13 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivatives
TW374919B (en) * 1997-08-28 1999-11-21 Hitachi Ltd Synchronous memory unit
US5919937A (en) 1997-10-29 1999-07-06 Merck & Co., Inc. Process for phosphodiesterase IV inhibitors
DE69813895T2 (de) 1997-11-25 2003-11-06 Warner-Lambert Co. Llc, Morris Plains Phenolsulfonamide als pde-iv inhibitoren und ihre therapeutische verwendung
EP1049676B1 (en) 1997-12-24 2005-10-12 Ortho-Mcneil Pharmaceutical, Inc. 4- aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor
US6180650B1 (en) 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6200993B1 (en) 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
GB2350110A (en) 1999-05-17 2000-11-22 Bayer Ag Pharmaceutically active benzofurans
JP4649046B2 (ja) 1999-05-21 2011-03-09 ブリストル−マイヤーズ スクイブ カンパニー キナーゼのピロロトリアジン阻害剤
JP4434362B2 (ja) 1999-06-28 2010-03-17 興和創薬株式会社 ホスホジエステラーゼ阻害剤
EP1116711B1 (de) 1999-12-18 2005-12-14 Wella Aktiengesellschaft 2-Aminoalkyl-1,4-diaminobenzol-Derivate und diese Verbindungen enthaltende Färbemittel
BR0116452A (pt) 2000-12-21 2003-09-30 Glaxo Group Ltd Composto, composição farmacêutica, uso de um composto
US6699890B2 (en) 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
AU2003256616B2 (en) * 2002-07-19 2009-08-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004046A1 (en) * 1993-07-28 1995-02-09 Rhone-Poulenc Rorer Limited Compounds as pde iv and tnf inhibitors
JPH09509654A (ja) * 1994-01-26 1997-09-30 ローン−プーラン・ロレ・リミテツド サイクリックａｍｐホスホジエステラーゼおよびｔｎｆ阻害剤としての置換芳香族化合物
JP2000501742A (ja) * 1995-12-15 2000-02-15 メルク フロスト カナダ アンド カンパニー Ｐｄｅ▲ｉｖ▼阻害剤としてのトリアリールエタン誘導体
JP2000509719A (ja) * 1996-06-19 2000-08-02 ローン―プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
JPH11189577A (ja) * 1997-12-25 1999-07-13 Nikken Chem Co Ltd ３−アニリノ−２−シクロアルケノン誘導体
JP2002502851A (ja) * 1998-02-09 2002-01-29 ダーウィン・ディスカバリー・リミテッド ベンゾフラン−４−カルボキサミドとその治療的使用
JP2002537383A (ja) * 1999-02-25 2002-11-05 メルク フロスト カナダ アンド カンパニー Ｐｄｅｉｖ阻害化合物、組成物および治療方法
WO2001070738A2 (en) * 2000-03-23 2001-09-27 Merck Frosst Canada & Co. Tri-aryl-substituted-ethane pde4 inhibitors
WO2001090076A1 (en) * 2000-05-25 2001-11-29 Merck Frosst Canada & Co. Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
WO2002074726A2 (en) * 2001-01-22 2002-09-26 Memory Pharmaceuticals Corporation Aniline derivatives useful as phosphodiesterase 4 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010012105, Ｄ．Ｇ．ＭｃＧａｒｒｙ ｅｔ ａｌ．, "Ｂｅｎｚｏｆｕｒａｎ ｂａｓｅｄ ＰＤＥ４ ｉｎｈｉｂｉｔｏｒｓ", Ｂｉｏｏｒｇａｎｉｃ ＆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ, 1999, Ｖｏｌ．７, ｐｐ．１１３１−１１３９ *
JPN6010012109, Ｔｈｏｍａｓ Ｊ Ｍａｒｔｉｎ, "ＰＤＥ４ ｉｎｈｉｂｉｔｏｒｓ − Ａ ｒｅｖｉｅｗ ｏｆ ｔｈｅ ｒｅｃｅｎｔ ｐａｔｅｎｔ ｌｉｔｅｒａｔｕｒｅ", ＩＤｒｕｇｓ, 2001, Ｖｏｌ．４， Ｎｏ．３, ｐｐ．３１２−３３８ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513957A (ja) * 2003-12-11 2007-05-31 メモリー ファーマシューティカルス コーポレーション Ｎ−置換ジアリールアミン類縁体を含む，ホスホジエステラーゼ４阻害剤本出願は，参照によりその全開示がここに導入されている２００３年１２月１１日に提出した米国仮出願番号６０／５２８，４８６の利益を請求するものである。
WO2008105386A1 (ja) * 2007-02-27 2008-09-04 National University Corporation Okayama University アルコキシ基を有するレキシノイド化合物
JPWO2008105386A1 (ja) * 2007-02-27 2010-06-03 国立大学法人 岡山大学 アルコキシ基を有するレキシノイド化合物
JP4691619B2 (ja) * 2007-02-27 2011-06-01 国立大学法人 岡山大学 アルコキシ基を有するレキシノイド化合物
US8389538B2 (en) 2007-02-27 2013-03-05 National University Corporation Okayama University Rexinoid compound having alkoxy group
JP2011517687A (ja) * 2008-04-14 2011-06-16 シエシー ファルマセウティチィ ソシエタ ペル アチオニ ホスホジエステラーゼ−４阻害剤としての第３アミン誘導体
WO2010041449A1 (ja) * 2008-10-09 2010-04-15 国立大学法人 岡山大学 Rxr作動性物質を有効成分とする抗アレルギー剤

Also Published As

Publication number Publication date
CN1714081A (zh) 2005-12-28
AU2003295656A1 (en) 2004-06-15
US20100173942A1 (en) 2010-07-08
KR20050075430A (ko) 2005-07-20
RU2005119627A (ru) 2006-01-27
NZ540138A (en) 2008-07-31
ATE481387T1 (de) 2010-10-15
EP1569908B1 (en) 2010-09-15
CA2506297A1 (en) 2004-06-03
NO20052976D0 (no) 2005-06-17
EP1569908A2 (en) 2005-09-07
US7700631B2 (en) 2010-04-20
CN100513397C (zh) 2009-07-15
US7087625B2 (en) 2006-08-08
US20060211865A1 (en) 2006-09-21
AU2003295656A2 (en) 2005-06-30
WO2004046113A2 (en) 2004-06-03
AU2003295656B2 (en) 2010-11-11
ZA200503995B (en) 2006-08-30
MXPA05005345A (es) 2005-08-26
WO2004046113A3 (en) 2005-03-24
US20040152902A1 (en) 2004-08-05
RU2356893C2 (ru) 2009-05-27
DE60334243D1 (de) 2010-10-28
NO20052976L (no) 2005-08-18
BR0315705A (pt) 2005-09-06

Similar Documents

Publication Publication Date Title
JP2006508987A (ja) ホスホジエステラーゼ４阻害剤
KR100856622B1 (ko) 포스포디에스테라제 4 억제제
JP2006504656A (ja) Ｎ−置換されたアニリン及びジフェニルアミンアナログを含むホスホジエステラーゼ４インヒビター
JP2007513957A (ja) Ｎ−置換ジアリールアミン類縁体を含む，ホスホジエステラーゼ４阻害剤本出願は，参照によりその全開示がここに導入されている２００３年１２月１１日に提出した米国仮出願番号６０／５２８，４８６の利益を請求するものである。
US20070049611A1 (en) Phosphodiesterase 4 inhibitors
US7655802B2 (en) Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) Phosphodiesterase 4 inhibitors
US7153871B2 (en) Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
HK1081194B (en) 6-amino-1h-indazole compounds as phosphodiesterase 4 inhibitors, pharmaceutical compositions comprising the same, and use thereof
HK1066215B (en) Aniline derivatives useful as phosphodiesterase 4 inhibitors
KR20050019904A (ko) Ｎ-치환된 아닐린 및 디페닐아민 유사체를 포함하는포스포디에스테라제 4 억제제
NZ547469A (en) 6-Amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061221

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100608

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100909

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101005

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20110222